Risk of death from breast cancer after treatment for ductal carcinoma in situ. BJS 2017; 104: 1506-1513.
Published: 22nd August 2017
Authors: C. Wadsten, H. Garmo, I. Fredriksson, M. Sund, F. Wärnberg
Studies to date have failed to demonstrate any survival benefit from preventing local recurrence after treatment for ductal breast carcinoma
A nested case–control study was conducted in a population‐based cohort of women with primary
From a cohort of 6964 women, 96 who died from breast cancer were identified and these were compared with a group of 318 controls. Tumour size over 25 mm or multifocal
In the present study, large tumour size and positive or uncertain margin status were associated with a higher risk of death from breast cancer after treatment for primary
You may also be interested in
Authors: M. Xiao, C. Lou, H. Xiao, Y. Yang, X. Cai, C. Li et al.
Notes: New molecular target for TNBC?
International validation of the European Organisation for Research and Treatment of Cancer QLQ‐BRECON23 quality‐of‐life questionnaire for women undergoing breast reconstruction.
Authors: Z. E. Winters, M. Afzal, C. Rutherford, B. Holzner, G. Rumpold, R. A. da Costa Vieira et al.
Notes: Useful tool
Axillary tumour burden in women with a fine‐needle aspiration/core biopsy‐proven positive node on ultrasonography compared to women with a positive sentinel node. BJS 2017; 104: 1811-1815.
Authors: P. Lloyd, E. Theophilidou, R. G. Newcombe, L. Pugh, A. Goyal
Notes: Axillary ultrasound can detect low‐volume metastases
Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. BJS 2017; 104: 1675-1685.
Authors: A. Karakatsanis, K. Daskalakis, P. Stålberg, H. Olofsson, Y. Andersson, S. Eriksson et al.
Notes: Simplifies logistics
Authors: M. Ahmed, M. Douek
Improved prognosis of young patients with breast cancer undergoing breast‐conserving surgery. BJS 2017; 104: 1802-1810.
Authors: E. Botteri, P. Veronesi, J. Vila, N. Rotmensz, V. Galimberti, M. V. Thomazini et al.
Notes: Molecular subtype matters most
Authors: R. N. Pedersen, K. Bhaskaran, U. Heide‐Jørgensen, M. Nørgaard, P. M. Christiansen, N. Kroman et al.
Notes: No correlation
Nomograms for preoperative prediction of axillary nodal status in breast cancer. BJS 2017; 104: 1494-1505.
Authors: L. Dihge, P.‐O. Bendahl, L. Rydén
Notes: Defines need for staging?
Authors: J. R. Benson, S. K. Down
Authors: R. V. Dave, R. Millican‐Slater, D. Dodwell, K. Horgan, N. Sharma
Notes: Mid‐neoadjuvant chemotherapy MRI useful
Combined PET–CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node‐positive breast cancer after neoadjuvant therapy. BJS 2017; 104: 1188-1196.
Authors: B. B. Koolen, M. Donker, M. E. Straver, M. E. M. van der Noordaa, E. J. T. Rutgers, R. A. Valdés Olmos et al.
Notes: Reduced axillary lymph node dissection rates
Quality of life after mastectomy with or without immediate breast reconstruction. BJS 2017; 104: 1197-1206.
Authors: J. Dauplat, F. Kwiatkowski, P. Rouanet, E. Delay, K. Clough, J. L. Verhaeghe et al.
Notes: Good for the appropriate patient